|
Once-daily AZILECT® 1 mg as initial monotherapy improves total UPDRS scores.1,2*
Improves total UPDRS scores.1,2
• AZILECT® treatment improved PD symptoms at 6 months compared to placebo (-3.8 units, P=0.0001) assessed as the change from baseline.
The Unified Parkinson’s Disease Rating Scale (UPDRS), a commonly used research tool in PD, is a multi-item rating scale that measures the ability of a patient to perform mental and motor tasks as well as activities of daily living. A reduction in the score represents improvement, and a beneficial change from baseline appears as a negative number.3,4
Allows early stage patients to stay active longer.1,5*
• AZILECT® treatment maintained activities of daily living (ADL) better than placebo (1.2 units vs 0.2 units; P=0.0003) assessed as the change from baseline. ADL measured on a scale from 0-52. Mean baseline score for placebo was 6.2; AZILECT® was 5.9.
Improves patients’ overall motor symptoms.1,5*
• AZILECT® treatment had a significant beneficial effect on motor symptoms compared to placebo (-0.4 vs 2.3 units; P<0.0001) assessed as the change from baseline. Motor measured on a scale from 0-108. Mean baseline score for placebo was 17.6; AZILECT® was 17.9.
• UPDRS motor consists of tremor, bradykinesia, rigidity, and postural instability and gait disorder (PIGD).3
Please see important safety information and complete prescribing information.
*Results from TEMPO, a double-blind, parallel-group, 26-week trial, conducted by the Parkinson Study Group, in early Parkinson’s disease patients not yet receiving dopaminergic therapy at the start of the study. The primary measure of effectiveness was the change from baseline in the total UPDRS score.
REFERENCES
1. The Parkinson Study Group. A controlled trial of rasagiline in early Parkinson disease. The TEMPO study. Arch Neurol. 2002;59(12):1937-1943.
2. AZILECT® Prescribing Information.
3. Fahn S, Elton RL, UPDRS Development Committee. Unified Parkinson’s Disease Rating Scale. In: Fahn S, Marsden CD, Calne DB, Goldstein M, eds. Recent Developments in Parkinson’s Disease. Florham Park, NJ: Macmillan; 1987:153-163, 293-304.
4. Waters CH. Diagnosis and Management of Parkinson’s Disease. 3rd ed.West Islip, NY: Professional Communications, Inc.; 2002.
5. Data on file, Teva Neuroscience, Inc.
|